Rate Video

EBMT 2020 | RACE: evaluating eltrombopag in severe aplastic anemia

Regis Peffault de Latour • 3 Sep 2020

EBMT 2020

Anemia Aplastic Anemia Rare Diseases Cyclosporine Eltrombopag Horse antithymocyte globulin

Race

Régis Peffault de Latour, MD, PhD, Saint-Louis Hospital, Paris, France, presents results from the RACE trial (NCT02099747), a prospective, randomized multicenter study comparing horse antithymocyte globulin and cyclosporine A with or without eltrombopag as front-line therapy for severe aplastic anemia patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Bettering the outcomes of transplant with the French biobank project

Regis Peffault de Latour • 26 Mar 2017

Transplantation for PNH?

Regis Peffault de Latour • 18 Mar 2018

Overview of HSCT and GvHD at EBMT

Regis Peffault de Latour • 3 Sep 2020

Advances in transplantation and drug treatments for idiopathic aplastic anemia

Regis Peffault de Latour • 18 Mar 2018

Related Videos

Progression risk stratification of asymptomatic WM

Romanos Sklavenitis-Pistofidis

Founding precision therapy for 1q-amplified multiple myeloma

Romanos Sklavenitis-Pistofidis

CXCR4 in Waldenström’s macroglobulinemia

LentiGlobin BB305 for β-Thalassemia

Christian Chabannon